AskGene Closes USD 20M Series A Financing
Summary
AskGene Limited, a Camarillo, CA- and Nanjing, China-based clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, closed a USD 20m Series A financing. The round was led by Qiming Venture Partners and TF Capital. Led by Jeff Lu, Chief Executive Officer, AskGene is advancing immunotherapies for cancers and autoimmune diseases. Through its SmartKine® platform technology and pipeline programs, the company aims to achieve its objective of modulating immune system at a disease site with selectivity and precision. Additional clinical stage programs include ASKB589 (an anti-CLDN 18.2 antibody in phase I/II) and ASKG712 (an anti-VEGF antibody-ANG2 antagonist peptide fusion molecule in phase I).
Funding
Review available funding amount, funding date, investors, and linked company information related to AskGene Closes USD 20M Series A Financing in the interactive ISVWorld profile.